Netrin–DCC inhibition suppresses neuroendocrine neoplasm growth in vivo
Endocrine-Related Cancer · 2025
DOI: 10.1530/erc-25-0226 ↗Kurz gefasst
Fachartikel in der Zeitschrift Endocrine-Related Cancer, 2025. Verfasst von Liav Sela Peremen und 4 weiteren Autor:innen. Beteiligte Einrichtung: Gray Faculty of Medical & Health Sciences, Tel-Aviv University, Tel Aviv-Yafo, Israel. Hauptthemen laut MEDLINE: DCC Receptor, Neuroendocrine Tumors, Pancreatic Neoplasms, Netrins. Die Arbeit nennt 37 Literaturangaben.
Abstract (Originalsprache)
DCC protein functions as a tumor suppressor and is altered in various tumors, including neuroendocrine neoplasms. Netrin (NTN)-1 serves as the primary ligand for DCC. Acting as a dependence receptor, DCC induces apoptosis in the absence of NTN and promotes cell survival when NTN is present. In certain cancers, such as small-cell lung cancer and neuroblastoma, the upregulation of NTN-3 has been observed instead of NTN-1. However, the exact role of NTNs and DCC in PNEN remains unclear. We assessed DCC and netrin expression in pancreatic neuroendocrine neoplasm (PNEN) cells (BON-1). We examined the effect of netrin on cell viability using DCC knockdown and NP137, a netrin-inhibiting antibody. In vivo , PNEN cells were injected into nude mice and treated with NP137 or PBS. Tumor RNA sequencing was performed. A population-based analysis using TCGA data evaluated the impact of DCC and NTN3 expression on survival. BON-1 cells exhibited elevated expression of DCC and NTN-3. The addition of NTN-1 augmented BON-1 viability, a response that was lessened upon NTN blockade using NP137. Furthermore, DCC siRNA negated the effect of NTN-1 on cell viability. Mice bearing PNEN BON-1 xenografts treated with NP137 exhibited markedly diminished xenograft growth. RNA sequencing revealed upregulation of small nucleolar RNAs (SNORs) in NP137-treated tumors, with enriched pathways related to RNA processing. TCGA analysis showed a negative correlation between NTN3 expression and survival. In conclusion, our data suggest that NTN-3, NTN-1, and DCC have interdependent oncogenic roles in PNENs, which can be reversed by blocking NTN binding to DCC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Gray Faculty of Medical & Health Sciences, Tel-Aviv University, Tel Aviv-Yafo, Israel.
- ENTIRE - Endocrine Neoplasia Translational Research Center, Research Center for Endocrinology, Diabetes and Metabolism, The Chaim Sheba Medical Center, Tel HaShomer, Israel.
ORCID-Profile: Amit Tirosh
Zitieren
APA
Sela Peremen, L., Telerman, A., Kahan Yossef, Y., Peshes Yaloz, N., & Tirosh, A. (2025). Netrin–DCC inhibition suppresses neuroendocrine neoplasm growth in vivo. Endocrine-Related Cancer. https://doi.org/10.1530/erc-25-0226
Vancouver
Sela Peremen L, Telerman A, Kahan Yossef Y, Peshes Yaloz N, Tirosh A. Netrin–DCC inhibition suppresses neuroendocrine neoplasm growth in vivo. Endocrine-Related Cancer. 2025. doi:10.1530/erc-25-0226
BibTeX
@article{SelaPeremen2025,
author = {Sela Peremen, Liav and Telerman, Alona and Kahan Yossef, Yuval and Peshes Yaloz, Naama and Tirosh, Amit},
title = {Netrin–DCC inhibition suppresses neuroendocrine neoplasm growth in vivo},
journal = {Endocrine-Related Cancer},
year = {2025},
doi = {10.1530/erc-25-0226}
}
EUVIMED